Related Experiment Video
Updated: Jan 15, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Neoadjuvant Chemoimmunotherapy in Non-small-cell Lung Cancer Patients: Effects on Pulmonary Function and Incidence of
Jian Zhang1, Yi Feng2, Shaohua Dai1
1Department of Thoracic Surgery, Jiangxi Clinical Research Center for Respiratory Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Objectives:
To evaluate the effects of neoadjuvant chemoimmunotherapy on pulmonary function and the incidence of postoperative pulmonary complications in real-world non-small-cell lung cancer patients.
Methods:
A retrospective analysis of stage II-IIIB non-small-cell lung cancer patients who received neoadjuvant chemoimmunotherapy across 3 medical institutions was conducted. Clinical data and perioperative outcomes were evaluated.
Results:
A total of 386 patients were screened and enrolled in the study cohort, and all patients underwent surgery after completing neoadjuvant chemoimmunotherapy. Postoperatively, 61 patients developed postoperative pulmonary complications, among whom 25 were diagnosed with checkpoint inhibitor-related pneumonia. The postoperative mortality rate was 2.8% (11/386), with all deaths attributed to severe postoperative checkpoint inhibitor-related pneumonia. The diffusing capacity of the lung for carbon monoxide tended to decrease after neoadjuvant chemoimmunotherapy, with 39% of patients developing impaired pulmonary function post-treatment. After controlling for confounding variables via propensity score matching analysis, impaired pulmonary function after treatment was associated with postoperative pulmonary complications. Multivariable logistic regression analysis revealed that prior lung disease (odds ratio, [OR]: 1.63; 95% CI, 1.02-3.31, P = .037), impaired pulmonary function after treatment (OR: 2.78; 95% CI, 1.38-5.24, P < .001), lymph node metastasis (OR: 3.05; 95% CI, 1.65-6.21, P < .001), and elevated preoperative interleukin-6 levels (OR: 1.58; 95% CI, 1.36-1.83, P < .001) were high risk factors for postoperative pulmonary complications.
Conclusions:
Impaired pulmonary function after neoadjuvant chemoimmunotherapy is associated with the development of postoperative pulmonary complications. Post-treatment impaired pulmonary function, lymph node metastasis, prior lung disease, and elevated preoperative interleukin-6 levels are risk factors for postoperative pulmonary complications.
Clinical Registration Number:
A Retrospective Study on Pulmonary Function Changes and Safety in Patients Receiving Neoadjuvant Chemoimmunotherapy (IIT2024733).
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:25Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...